Selected Experience With Surgery and Combination Chemotherapy in the Treatment of Nonseminomatous Testis Tumors
- 1 May 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 129 (5) , 985-988
- https://doi.org/10.1016/s0022-5347(17)52500-8
Abstract
Patients (208) were treated with newly diagnosed nonseminomatous germ cell tumors of the testis between Jan. 1975 and Mar. 1978. Patients with stages I and II disease underwent retroperitoneal lymph node dissection, and the majority of patients with stage II neoplasm received adjuvant chemotherapy afterwards. Patients with stage III and palpable stage II neoplasm had initial chemotherapy with or without subsequent surgery. The overall cure rates were 96% (76 of 79) for patients with stage A, 94% (31 of 33) with stage IIA, 83% (35 of 42) with stage IIB and 35% (15 of 43) with stage III disease. The stage of disease at the time of diagnosis, local extent of the primary tumor, nodal category in stages I and II cancer and chemotherapy were factors influencing relapse rate and overall survival.This publication has 8 references indexed in Scilit:
- VAB-3 combination chemotherapy of metastatic testicular cancerCancer, 1981
- Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancerCancer, 1981
- Adjuvant Chemotherapy in Non-Seminomatous Testis Cancer: “Mini-Vab” Regimen: Long-Term FollowupJournal of Urology, 1981
- VAB–4 combination chemotherapy in the treatment of metastatic testis tumorsCancer, 1981
- GERM-CELL TUMORS OF THE TESTIS - IMPROVED RESULTS IN A PROSPECTIVE-STUDY USING COMBINED MODALITY THERAPY AND BIOCHEMICAL TUMOR-MARKERS1979
- Improved management of nonseminomatous testis tumorsCancer, 1978
- Germ cell tumors (II). VAB II in metastatic testicular cancerCancer, 1978
- Testicular tumors. A clinicopathological studyCancer, 1953